静脉化疗保留E组视网膜母细胞瘤合并新生血管性青光眼患眼的风险因素与结局
这项回顾性比较干预病例系列纳入37只接受静脉化疗的E组视网膜母细胞瘤合并新生血管性青光眼患眼,21只行二期眼球摘除,16只保眼成功。症状持续时间、初诊眼压、角膜直径增加及无菌性眶蜂窝织炎与二期眼球摘除相关,多因素分析显示初诊年龄>6个月和牛眼为独立风险因素,平均随访20.5个月无全身转移。
要点
- 初诊年龄<6个月、症状持续<10周、眼压<26 mmHg且无牛眼和无菌性眶炎症时保眼机会更好。
- 二期眼球摘除组症状持续更长、初诊眼压更高、角膜直径增加更多且无菌性眶蜂窝织炎更多。
- 平均随访20.5个月两组均未出现全身转移。
核心结论
- E组视网膜母细胞瘤合并新生血管性青光眼患眼经静脉化疗保眼成功与初诊年龄<6个月、症状持续<10周、眼压<26 mmHg、无牛眼及无无菌性眶炎症相关。
研究设计与样本
- 回顾性、比较性、干预性病例系列,共37只接受静脉化疗的E组视网膜母细胞瘤合并新生血管性青光眼患眼。
主要发现
- 37只眼中21只行二期眼球摘除(组1),16只保眼成功(组2)。
- 组1症状持续时间18.8周 vs 组2 5.4周(p=0.016)。
- 组1初诊眼压36 mmHg vs 组2 30 mmHg(p=0.044)。
- 组1角膜直径增加1.52 mm vs 组2 0.50 mm(p=0.013)。
- 组1无菌性眶蜂窝织炎9例 vs 组2 1例(p=0.023)。
关键数值与推荐
- 单因素分析中二期眼球摘除风险因素:症状持续>10周(p=0.003)、初诊眼压>26 mmHg(p=0.045)、牛眼(p=0.014)、无菌性眶蜂窝织炎(p=0.023)。
- 多因素分析中二期眼球摘除风险因素:初诊年龄>6个月(p=0.012)、牛眼(p=0.017)。
- 平均随访20.5个月,两组均无患者发生全身转移。
临床怎么用
- 对E组视网膜母细胞瘤合并新生血管性青光眼患眼,初诊年龄<6个月、症状持续<10周、眼压<26 mmHg且无牛眼和无菌性眶炎症者可优先考虑静脉化疗保眼。
- 初诊年龄>6个月或存在牛眼者二期眼球摘除风险较高,应加强评估与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: To report the outcomes of retinoblastoma group E eyes with neovascular glaucoma (NVG) treated conservatively with intravenous chemotherapy and investigate factors associated with eye salvage and secondary enucleation. METHODS: This is a retrospective, comparative, interventional case series. The outcome measures were life salvage, eye salvage and vision salvage. RESULTS: Of the 37 eyes managed by intravenous chemotherapy, secondary enucleation was necessary in 21 eyes (group 1) and eye salvage was possible in 16 eyes (group 2). A comparison of both groups revealed significant difference with group 1 demonstrating greater duration of symptoms (18.8 weeks vs 5.4 weeks, p=0.016), greater intraocular pressure (IOP) at presentation (36 mm Hg vs 30 mm Hg, p=0.044), greater increase in corneal diameter (1.52 mm vs 0.50 mm, p=0.013) and the presence of sterile orbital cellulitis (9 vs 1, p=0.023). Further, the risk factors for secondary enucleation by univariate analysis were duration of symptoms >10 weeks (p=0.003), presenting IOP >26 mm Hg (p=0.045), buphthalmos (p=0.014) and sterile orbital cellulitis (p=0.023) and by multivariate analysis were age at presentation >6 months (p=0.012) and buphthalmos (p=0.017). At a mean follow-up of 20.5 months, none of the patients in either group developed systemic metastasis. CONCLUSION: For retinoblastoma group E eyes presenting with NVG, the chance of eye salvage with intravenous chemotherapy is better when the age at diagnosis is <6 months, duration of symptoms is <10 weeks, IOP is <26 mm Hg, and in the absence buphthalmos and sterile orbital inflammation.
引用
- Rao R, Honavar SG, Reddy VP, et al. Preservation of retinoblastoma group E eyes with neovascular glaucoma using intravenous chemotherapy: risk factors and outcomes. Br J Ophthalmol. 2019. PMID: 30796055. doi:10.1136/bjophthalmol-2018-313442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。